Clinical Trial Detail

NCT ID NCT02759835
Title Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

lung adenocarcinoma

Therapies

Osimertinib

Age Groups: adult senior

Additional content available in CKB BOOST